Krishna Institute Of Medical Sciences Limited · NSE:KIMS
Krishna Institute Of Medical Sciences — Q2 FY24 Earnings Presentation
32 slides from Krishna Institute Of Medical Sciences's earnings presentation, Nov 7, 2023
Slide 1: Cover letter to stock exchanges: Investor Presentation
07th November 2023 The General Manager, The Manager, Department of Corporate Services Listing Department Bombay Stock Exchange Ltd (BSE) National Stock Exchange of India Limited, Phiroze Jheejheebhoy Towers, Exchange Plaza, 5th Floor, Dalal Street, Plot No.C/1, 'G' Block, Mumbai - 400 001. Bandra -
Slide 2: Q2 FY24 Update
Q2 FY24 UPDATE Private & Confidential
Slide 3: Driven by a Vision
Driven by a Vision Affordable Quality Care VISION: Best-in-Class Facilities Patient Centric Systems & Processes S To be the most preferred NT healthcare services brand by TIE providing affordable care and best PA clinical outcomes to patients. Clinical Outcome Driven Excellence And to be the best pl
Slide 4: Multi Specialty Care
Multi Specialty Care Brain Eyes Bones and Spine Radiology • Neurology • Ophthalmology • Orthopedics • Imaging • Neurosurgery Gastro Intestinal Tract • Arthroscopic Surgery • Interventional Radiology • Psychiatry • Medical Gastroenterology • Spine Surgery Lab Services • Neuro Rehabilitation • Surgica
Slide 5: KIMS at a Glance
KIMS at a Glance Telangana Secunderabad (1000) Maharashtra Paradise Circle (290) (Shifting to Begumpet) Nagpur (334) Kondapur (200) Nashik (Under Construction) Gachibowli (237) Thane (Under Construction) Andhra Pradesh Visakhapatnam (469) Srikakulam (200) Rajahmundry (195) Karnataka Ongole (350) Ben
Slide 6: Dr. B. Bhaskar Rao - Visionary Behind KIMS
Dr. B. Bhaskar Rao - Visionary Behind KIMS Chairman & Managing Director A legend in CT Surgery, Dr. Bollineni Bhaskar Rao {MBBS, MS, DNB (CT Surgery)} is one of the very few Cardio- Thoracic Surgeons in the country, who performed over 30000 surgeries in his career spanning over more than 25 years. W
Slide 7: Dr. Abhinay Bollineni
Dr. Abhinay Bollineni Chief Executive Officer Dr. Abhinay Bollineni joined KIMS Hospitals in 2013 and spent the next couple of years in Hospital Operations before taking charge of Strategy & Marketing for the Group in 2015. In a short span of 5 years, KIMS expanded and opened five additional units (
Slide 8: Board of Directors
Board of Directors Mr. Rajeswara Rao G Dr. Bhaskara Rao Bollineni Dr. Abhinay Bollineni Mrs. Anitha Dandamudi Shantanu Rastogi Independent Director, Chairman & Managing Director Chief Executive Officer Whole-time Director Non-Executive Director Chairman (Stakeholders’ Relationship Committee) Mr. Sau
Slide 9: Shareholding Pattern - As on 30 September 2023
Shareholding Pattern - As on 30 September, 2023 th Retail & Others, Retail Pre IPO, 4.0% 7.6% Promoter & Promoter Share Holder No of Shares Share Holding % Category Group, 38.8% Promoter 3,10,86,304 38.8% ICICI Ventures 19,39,393 2.4% Sbi MF 51,32,961 6.4% DII FII, 14.2% Axis MF 42,19,311 5.3% DII M
Slide 10: Modern Medical Technology
Modern Medical Technology 4-Arm HD da Vinci O-Arm Scanner Spy Glass Fibroscan Robotic Surgical Multi-dimensional surgical State of the art add on to Specialized non-invasive System imaging platform optimized ERCP that allows doctors to diagnostic ultrasound-based Facilitates complex for use in spine
Slide 11: Many Firsts...
Many Firsts... • First in Asia in to do Trans catheter • India’s first COVID Double Lung • Number 1 in Nephrology treatments in Tricuspid Valve replacement transplant done in 2020 Andhra Pradesh* procedure done in 2018 • India’s first Breathing Lung transplant • Number 1 in Neurosurgery & Poly • Lar
Slide 12: Key Accomplishments
Key Accomplishments NAL ACCRED ATIO IT N AT ER ION INT QU Y ET LI AF A TY & PAT I E N T S Pharmacie De Qualite (PDQ) American Accreditation Commission Certification Overall PDQ Evaluation ‘Best Patient Friendly Hospital’ Ranked No. 1 Hospital International (AACI) Performance Score - 98% AHPI Health
Slide 13: Consistent Performer over 2 decades
Consistent Performer over 2 decades (Rupees in Millions) 5,766 22,235 5,217*** 16,711 % 11,287 % 4 27.9 31 . GR: GR : C A A C 2,412 4,280 773 1,311 317 263 42 2005 2010 2015 2020 2022 2023** 2005 2010 2015 2020 2022 2023** No. of No. of No. of No. of No. of No. of Hospitals: 1 Hospitals: 3 Hospitals
Slide 14: Q2 FY24 Updates
Q2 FY24 Updates 13 Private & Confidential
Slide 15: Financial & Operational Highlights - 1/2
Financial & Operational Highlights - 1/2 (Rupees in Millions) FINANCIAL HIGHLIGHTS Q2 FY 24 Consolidated • Gross revenue at INR 655 Cr, a growth of 14.3% on a YoY and 7.6% on a QoQ basis. • Reported Operating EBITDA of INR 180 Cr, an increase of 11.5% YoY and 12.5% QoQ basis. • Reported EBITDA margi
Slide 16: Financial & Operational Highlights - 2/2
Financial & Operational Highlights - 2/2 FINANCIAL HIGHLIGHTS Q2 FY 24 Consolidated • Consolidated Revenue grew by 14.3% on a YoY and 7.6% on a QoQ basis to INR 655 Cr • Consolidated EBITDA (Pre-INDAS and excluding Other Income) grew by 19.1% on a YoY and 11.3% on a QoQ basis to INR 172 Cr • Consoli
Slide 17: Digital & ESG Initiatives
Digital & ESG Initiatives DIGITAL During the last quarter, KIMS continued its digitization journey with a goal of having 100% paperless business processes in all its operational, INITIATIVES clinical and finance verticals. As part of this journey, last quarter we have either initiated or delivered t
Slide 18: Group Operating Performance - 1/3
Group Operating Performance - 1/3 IP VOLUME (‘000) OP VOLUME (‘000) 10.6% 8.0% 177 51 1,462 413 47 46 375 382 137 12.8% 1,014 13.6% 97 795 86 700 FY22 FY23 H1FY23 H1FY24 Q2 FY23 Q1 FY24 Q2 FY24 FY22 FY23 H1FY23 H1FY24 Q2 FY23 Q1 FY24 Q2 FY24 OCCUPANCY* ARPOB (‘000) 6.0% 5.8% (1.8%) 79.8% 4.3% 76.4%
Slide 19: Group Operating Performance - 2/3
Group Operating Performance - 2/3 (Rupees in Millions) TOTAL REVENUE EBITDA* 7.6% 11.3% 22,235 6,554 5,766 1,723 5,733 6,091 5,122 1,548 1,447 16,711 17.7% 18.5% 12,645 3,270 10,741 2,759 FY22 FY23 H1FY23 H1FY24 Q2 FY23 Q1 FY24 Q2 FY24 FY22 FY23 H1FY23 H1FY24 Q2 FY23 Q1 FY24 Q2 FY24 PBT PAT 16.9% 16
Slide 20: Group Operating Performance - 3/3
Group Operating Performance - 3/3 Particulars FY22 FY23 H1 FY23 H1 FY24 Q2 FY23 Q1 FY24 Q2 FY24 Bed Capacity 3,064 3,940 4,015 3,975 4,015 3,975 3,975 Operational Beds 2,590 3,468 3,543 3,503 3,543 3,503 3,503 Census Beds 2,246 2,960 3,026 2,989 3,026 2,989 2,989 Non Census Beds 344 508 517 514 517
Slide 21: Comparison of Telangana and Andhra Pradesh Hospitals - 1/2
Comparison of Telangana and Andhra Pradesh Hospitals - 1/2 Telangana (KIMS) Andhra Pradesh (KIMS) Particulars FY22 FY23 Q2 FY23 Q1 FY24 Q2 FY24 H1 FY24 FY22 FY23 Q2 FY23 Q1 FY24 Q2 FY24 H1 FY24 Bed Capacity 1,200 1,200 1,200 1,200 1,200 1,200 1,864 1,879 1,879 1,914 1,914 1,914 Operational Beds 1,03
Slide 22: Comparison of Sunshine, Nagpur & Group - 2/2
Comparison of Sunshine, Nagpur & Group - 2/2 Sunshine Nagpur Group Particulars FY23 Q2 FY23 Q1 FY24 Q2 FY24 H1 FY24 FY23** Q2 FY23** Q1 FY24 Q2 FY24 H1 FY24 FY22 FY23 Q2 FY23 Q1 FY24 Q2 FY24 H1 FY24 Bed Capacity 527 602 527 527 527 334 334 334 334 334 3,064 3,940 4,015 3,975 3,975 3,975 Operational
Slide 23: Speciality Mix
Speciality Mix Others Cardiac Science 22% 18% Renal Sciences 9% Mother & Child 9% Group H1 FY24 Organ Oncology Transplant 5% 3% Gastric Sciences 8% Neuro Sciences 12% Orthopaedics 14% 22 Private & Confidential
Slide 24: Payor & Cluster Profile
Payor & Cluster Profile PAYOR MIX CLUSTER TOTAL REVENUE Maharashtra 7% Andhra Pradesh Aarogyasri 27% 7% Cash Telangana Corporate Group 66% 14% 53% H1 FY24 Group H1 FY24 CLUSTER EBITDA* Maharashtra Insurance 3% 26% Andhra Pradesh 24% Group Telangana 73% H1 FY24 *EBITDA before IND AS and other income
Slide 25: Key Achievements in Q2 FY24
Key Achievements in Q2 FY24 24 Private & Confidential
Slide 26: Key Achievements in Q2 FY24
Key Achievements in Q2 FY24 25 Private & Confidential
Slide 27: Key to our success
Key to our success Doctor Affordable Partnerships Quality Care Modern Medical Infra 26 Private & Confidential
Slide 28: Disciplined growth strategy in adjacent markets
KIMS has a disciplined growth strategy - strategically grow in adjacent markets some of which are ‘natural extensions’ KIMS Plans to Grow into Markets that are Adjacent to the Current Core Markets of AP and Telangana Central & Western India (Mumbai, Indore, Aurangabad, Nagpur & Raipur): KIMS flagshi
Slide 29: Expansion plans
Expansion plans Current Incremental New Approx. Expected Year of Units Beds Beds Departments Capex Operation Nashik - 300 All Specialities 200-250 Cr Q1 FY25 Mumbai (Thane) - 300 All Specialities 225-250 Cr Q4 FY25 Bangalore - 415 All Specialities 350-400 Cr Q4 FY25 Cancer Centre / Anantapur 250 200
Slide 30: Profit and Loss Statement
Profit and Loss Statement (Rupees in Millions) Consolidated Particulars Q2 FY 24 Q1 FY 24 Q2 FY 23 QoQ(%) YoY(%) H1 FY 24 H1 FY 23 YoY(%) Operating Revenue 6,525 6,060 5,641 7.7% 15.7% 12,585 10,596 18.8% Other Income 29 31 92 -7.3% -68.6% 60 145 -58.7% Total Revenue 6,554 6,091 5,733 7.6% 14.3% 12,
Slide 31: Corporate Structure (As on 30 September 2023)
Corporate Structure (As on 30 September'23) th Krishna Institute of Medical Sciences Ltd. KIMS Secunderabad KIMS Nellore KIMS Rajahmundry KIMS Ongole (100%) (100%) (100%) (100%) AHPL KHEPL KIMS ICON KIMS Saveera KIMS Sunshine KIMS-Manavata SPANV KIMS Hospitals Srikakulam Kondapur Visakhapatnam Anant
Slide 32: Thank You
Thank You 31 Private & Confidential
Krishna Institute of Medical Sciences — Q2 FY24 Earnings Presentation on 6ix